Cavion LLC Expands Drug Discovery Program
Makes Key Hire for Chemistry Team

(Charlottesville, Va. -- October 14, 2015) Cavion LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of neurologic diseases and solid tumors, announced that it has hired Thomas Richardson, PhD, as Director of Chemistry Discovery and Development. Dr. Richardson will work toward expanding the company’s platform of novel T-type calcium channel inhibitors through drug discovery and assessing in-licensing opportunities.

Dr. Richardson received his doctorate in Organic Chemistry from The Ohio State University and brings to Cavion fifteen years’ experience as a medicinal chemist in the pharmaceutical industry, most recently serving as Research Investigator in the Medicinal Chemistry Division of SCYNEXIS, Inc.

“I look forward to working with Dr. Richardson to identify and develop novel T-type calcium channel inhibitors to move into, and through, the discovery process,” stated Cavion President and CEO Andrew Krouse. “These new compounds will complement Cavion’s clinical stage assets for oncology and neurology.”

Cavion also expanded its staff by hiring Allison de Almeida, a graduate of The Pennsylvania State University, as Analyst and Evan Newbold, a graduate of Lafayette College, as Science Research Analyst.

About Cavion LLC

Cavion LLC, founded as Tau Therapeutics LLC, is a privately held clinical stage platform pharmaceutical company creating therapies engaging the T-type calcium channel (Cav3) for the treatment of neurologic and oncologic diseases. The T-type calcium channel is an emerging molecular target for cancer and pain.

Cavion is co-sponsoring a Phase 1 trial (NCT02202993) of the T-type calcium channel blocker mibefradil combined with hypofractionated radiation therapy for the treatment of recurrent glioblastoma multiforme with the Yale University Comprehensive Cancer Center. A multi-site NCI Adult Brain Tumor Consortium-sponsored Phase 1b clinical trial (NCT01480050) of mibefradil administered with temozolomide in brain cancer recently completed enrollment. Cavion intends to launch its first neurology clinical trial in 2016.

Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Cavion LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.